Company Filing History:

25 out of 1,164

Boehringer Mannheim Gmbh

patents

1 out of 1

C.f. Boehringer & Soehne Gmbh

patent

1 out of 480

Roche Diagnostics Gmbh

patents

Years Active: 1976-2001

Loading Chart...

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6326378 - Use of thiadiazolo[4,3-a]pyridine derivatives (2001-12-04),

2. 4810801 - Pyrrolobenzimidazoles, pharmaceutical compositions containing them, and (1989-03-07),

3. 4710510 - Pyrrolobenzimidazoles, pharmaceutical compositions containing them, and (1987-12-01),

4. 4704381 - Use of adenosine derivatives as anti-allergic compounds and (1987-11-03),

5. 4642309 - Indolin-2-one derivatives preparation thereof and intermediates for the (1987-02-10),

6. 4486442 - Anti-allergy bicyclic phenol ethers (1984-12-04),

7. 4461763 - Oximes of 3''-dehydrocardenolide tridigitoxosides (1984-07-24),

8. 4436735 - Ketals of 3''-dehydrocardenolide tridigitoxosides (1984-03-13),

9. 4387104 - N-Substituted pyruvic acid hydrazones, preparation thereof and (1983-06-07),

10. 4353895 - Cardenolide-bis-digitoxoside alkyl compounds, pharmaceutical (1982-10-12),

11. 4348401 - N-Phenoxyalkylpiperidine derivatives (1982-09-07),

12. 4292314 - Cardioactive 12-dehydrodigoxin-oximes (1981-09-29),

13. 4288442 - Inhibiting adrenergic .beta.-receptors with piperidinopropyl derivatives (1981-09-08),

14. 4229464 - Aminopropanol substituted indole compounds and compositions for the (1980-10-21),

15. 4212866 - Pharmaceutically active derivatives of (1980-07-15),

Title: Innovations and Contributions of Wolfgang Schaumann

Introduction

Wolfgang Schaumann is a prominent inventor based in Heidelberg, Germany, known for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 27 patents, Schaumann has made notable advancements in the treatment of various medical conditions, including leukemia and cardiovascular diseases.

Latest Patents

Among his most recent patents is an innovative method for treating leukemia and lymphoma using thiadiazolo[4,3-a]pyridine derivatives. This groundbreaking invention focuses on the inhibition of cell proliferation with specific compounds of formula I. Additionally, he has developed new pyrrolobenzimidazoles, detailing their chemical formulations and highlighting their utility in pharmaceutical compositions aimed at preventing and treating heart and circulatory diseases.

Career Highlights

Throughout his career, Wolfgang Schaumann has worked with notable companies, including Boehringer Mannheim GmbH and C.F. Boehringer & Soehne GmbH. His work in these organizations has allowed him to deepen his research and development expertise, leading to a series of impactful inventions that address critical health challenges.

Collaboration

Schaumann has collaborated with esteemed colleagues, including Wolfgang Kampe and Max Thiel, who have contributed to the development of his patented innovations. These partnerships have facilitated the sharing of knowledge and expertise, further enriching the quality and scope of their collective research efforts.

Conclusion

Wolfgang Schaumann's work exemplifies the spirit of innovation in the pharmaceutical industry. His patents not only showcase his inventive capabilities but also highlight his commitment to improving human health. As he continues to develop new solutions, the impact of his work will undoubtedly resonate within the medical community and beyond.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com